SHEL.UK

3,308

+0.3%↑

572

+0.51%↑

REN

31.14

+0.71%↑

SDR

578.5

0%↓

PSON

1,074.5

-0.19%↓

SHEL.UK

3,308

+0.3%↑

572

+0.51%↑

REN

31.14

+0.71%↑

SDR

578.5

0%↓

PSON

1,074.5

-0.19%↓

SHEL.UK

3,308

+0.3%↑

572

+0.51%↑

REN

31.14

+0.71%↑

SDR

578.5

0%↓

PSON

1,074.5

-0.19%↓

SHEL.UK

3,308

+0.3%↑

572

+0.51%↑

REN

31.14

+0.71%↑

SDR

578.5

0%↓

PSON

1,074.5

-0.19%↓

SHEL.UK

3,308

+0.3%↑

572

+0.51%↑

REN

31.14

+0.71%↑

SDR

578.5

0%↓

PSON

1,074.5

-0.19%↓

Home・Aktien・Smith & Nephew PLC

Smith & Nephew PLC

Geschlossen

1,157 -2.94

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1155

Max

1161

Schlüsselkennzahlen
By Trading Economics
Einkommen	47M 342M
Verkäufe	318M 3.3B
KGV Branchendurchschnitt	23.774 77.607
EPS	0.429
Dividendenrendite	3.1
Gewinnspanne	10.36
Angestellte	16,988
EBITDA	162M 886M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+26.13% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	3.10% 3.49%

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-391M 11B
Vorheriger Eröffnungskurs	1159.94
Vorheriger Schlusskurs	1157

Smith & Nephew PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Smith & Nephew PLC Prognose

Kursziel

By TipRanks

26.13% Vorteil

12-Monats-Prognose

Durchschnitt 1,460.57 GBX 26.13%

Hoch 1,700 GBX

Tief 1,300 GBX

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Smith & Nephew PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

Buy

Halten

Sell

Basierend auf 7 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Smith & Nephew PLC – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.